Sugi Holdings7649.T
Pull Sugi’s reported net income apart and the cheapness dissolves. A 0.43% effective tax rate — a non-cash deferred-tax credit worth ~¥13.6bn — doped FY2/2026 earnings to ¥45.0bn against a normalised ~¥32bn, and the reported 11–12× P/E is an artefact. Underneath sits a genuine first-rank compounder: ROIC 12.0%, a +6.0pt spread, the best cash conversion in the bucket. The inherited hope was that the officine migration hid recurring value the consolidated multiple missed. Valued part by part, the sum falls below the price. What is left to decide is narrower: whether the officine is accretive at contribution once the pharmacist is paid — a number the company does not disclose.
The merchandise drugstore — 68% of sales, roughly ¥30.8bn of proxied segment EBITA — carries the value at the ~9× a regional Japanese drugstore earns: about ¥277bn. The officine pole, at ~¥17.8bn of EBITA on the ~10.5× a dispensing chain commands, adds ~¥187bn ; other services ~¥16bn.
The parts sum to an enterprise value of ~¥481bn, against the ~¥520.6bn the market assigns Sugi today.
Net of ¥96.5bn gross debt, ¥124.6bn of cash and an ¥11.6bn unfunded pension, equity reconstructs to ¥2,520–2,750 per share. Spot is ¥2,968.
The recurring value the inherited thesis was waiting to unlock is not in the numbers. On the parts, the market already pays an 8–15% premium.
The interesting thing about Sugi is not that it looks cheap, it is why it looks cheap and what that hides. On reported earnings the stock trades at 11–12×, the kind of number that flags a value opportunity in a defensive compounder. It is an illusion, and a triple one. The reported FY2/2026 net income of ¥45.0bn was earned at a 0.43% effective tax rate, doped by a non-cash deferred-tax credit worth roughly ¥13.6bn that the company has itself told the market will not recur — guidance for FY2/2027 puts net income down 27.1%. Correct the tax, correct the divisor for treasury stock, strip out the FY+1 fallback in the data pack, and the multiple resets to ~16.5× normalised earnings, the middle of Sugi’s own decade range. The stock is not cheap. It is fairly priced.
What the reported number hides is a genuine business. On the only quality metric this bucket rewards — the lease-adjusted spread of return on capital over its cost — Sugi prints ROIC of 12.0% against a ~6% cost of capital, a +6.0pt spread and first rank alongside Matsukiyo. It converts better than anyone in the sector: free cash flow ex-growth of ¥66.7bn, capital expenditure at 2.3% of sales, working capital close to neutral. The tax credit was doping the net income line ; it never touched the operating engine, which grew EBIT +14.1% in FY2/2026 and is guided +11.2% for FY2/2027. The quality is real, and it is not an artefact.
The dossier was inherited as a hidden-value story. Sugi has been migrating into the dispensing pharmacy — the officine, chōzai — which now runs 30.4% of sales and earns a 36.4% gross margin against 29.1% for the merchandise floor. The hope was that a recurring, higher-margin business was buried inside a consolidated multiple that could not see it, and that valuing the parts separately would release it. Valued part by part, it does not. The sum reconstructs to an enterprise value below the current one ; on the segment proxies the market already pays an 8–15% premium to the pieces. There is no recurring value to unlock.
The reason the parts do not add up is the one number the consolidated statement hides. The officine’s 36.4% gross margin looks like a structural edge over the 29.1% drugstore — a +7.2pt advantage. But the officine carries a cost the merchandise floor does not: the pharmacist, whose wage is pulled by a national shortage and rises ~3% a year, and which cannot be passed on because the dispensing price is fixed by the MHLW and cut every two years. Impute that cost and the +7.2pt gross advantage compresses to roughly +1pt at the contribution level — accretive, but modestly, not transformationally. Whether it stays accretive as the fee schedule falls is the question the whole thesis turns on, and Sugi does not disclose the number that answers it.
The position framing is watchlist coverage, not ownership. The weighted fair value sits a little below spot and the tail asymmetry is close to symmetric — bull +22%, bear −22%, neither dominant. Conviction is moderate, and it is conviction about the absence of asymmetry rather than a direction. Two things are worth watching, both on a published calendar: the 2026 fee-schedule revision, the concentrated downside the market under-prices, and any signal that the dormant balance sheet gets put to work.
The cleanest way to read the last decade is as three regimes stacked on a single fact: revenue nearly tripled while the operating margin drifted down. Sugi entered the decade as a regional drugstore compounder in Chūbu, earning a stable ~5.5% EBIT margin on a large net-cash balance sheet, growing organically and by store openings. It spent the back half turning into something else — a debt-financed consolidator of dispensing pharmacies, revenue ¥415bn to ¥1,010bn, officine share from the low twenties to 30.4%, and a reported net income that jumped on a tax credit it has already guided away. The shape matters because it makes any valuation anchored on a ten-year average multiple meaningless: the reported earnings line carries a doped peak the operating line never saw.
| Inflection | FY2/2016Regional | FY2/2021Pivot begins | FY2/2023Pre-I&H trough | FY2/2026Consolidator | FY2/2027eGuidance |
|---|---|---|---|---|---|
| Revenue (¥bn) | 414.9 | 602.5 | 667.6 | 1,010.3 | 1,092.0 |
| EBIT (¥bn) | 23.1 | 33.7 | 31.7 | 48.6 | 54.0 |
| EBIT margin | 5.57% | 5.59% | 4.74% | 4.81% | 4.95% |
| Gross margin | 27.9% | 29.9% | 30.6% | 31.8% | — |
| Return on capital | 11.1% | 10.9% | 8.8% | 13.3%* | — |
| FCF (¥bn) | 4.1 | 15.4 | 20.1 | 63.7* | — |
| Net debt (¥bn) | −80.2 | −93.5 | −68.7 | −14.7 | — |
| Net income (¥bn) | 14.6 | 21.1 | 19.0 | 45.0* | 32.8 |
Source: data pack 14 July 2026 + Excel (11 tabs), issuer close-year convention. Officine share of sales: 21.3% (FY2/2024) → 24.9% (FY2/2025) → 30.4% (FY2/2026). I&H / Hanshin Dispensing consolidated from FY2/2024 ; gross debt rose ¥2.8bn to ¥96.5bn to fund it. *Return on capital and net income in FY2/2026 are tax-doped (ETR 0.43%) ; on normalised NOPAT, ROIC ~12.0% and normalised net income ~¥32bn. FCF FY2/2026 is inflated by a one-off working-capital reflux. FY2/2027e net income −27.1% is the reflux of the tax credit, not an operating decline.
Three decisions shape the record. Restitution was chronically thin — a dividend that doubled in ten years on a ~20% payout, two episodic buybacks and nothing regular, while a large net-cash balance sat idle and diluted the return on capital. The I&H acquisition that built the pharmacy footprint was financed by quadrupling gross debt from ¥2.8bn to ¥96.5bn at the exact point BoJ rates began to normalise ; interest cover fell from ~2,400× to 55×. And that same acquisition let a reported net income jump on a non-recurring tax benefit without the company de-risking the market before guiding it down 27.1%. The discipline is real — ROIC held through the deal, net debt stayed negative — but it is not yet evidence of a durably better allocator, and the same dormant cash that could fund a repeat is still on the balance sheet.
The engine only makes sense once you split the consolidated line, because the two halves are economically different businesses sharing a floor. The merchandise drugstore — 68% of sales — is a mature, semi-discretionary retailer growing same-store at +2.4%, roughly inflation. The officine is the opposite: a recurring, captive, demographically-anchored prescription business growing same-store at +13.2%, the only structurally rising demand in Japan. A single 4.8% EBIT margin is the blend of a stagnant mass engine and a rising quality one, which is why one consolidated multiple is the wrong tool.
The thing to understand about Sugi’s revenue is that none of it carries pricing power, and the word is doing quiet work in the growth figures. The merchandise floor is a commoditised, price-matched market. The officine is administered — the dispensing price and fee are set by the MHLW and revised down every two years. The officine’s rising sales are volume at a falling price, the exact inverse of pricing power. The only levers of value are mix — the officine is gross-margin accretive — and the purchasing scale extracted from the acquisitions. Both are real and both are capped.
The cost that governs the whole engine is the pharmacist. It is the one input in the sector whose inflation cannot be passed on: the wage is pulled by a national shortage, indexed to Japanese wage growth at ~3%, and it rises while the administered price it serves is cut. The defence is density — a pharmacist processing more prescriptions on a denser network amortises a fixed cost — which is the entire economic logic of the I&H consolidation. The consolidation creates value only if it raises pharmacist occupancy, not merely if it adds pharmacies. At constant volume the officine’s operating leverage is negative: the price falls, the cost climbs.
The cash conversion is first-rank and is part of what protects the downside. Free cash flow ex-growth ran ¥66.7bn, the best in the bucket, on maintenance capital expenditure roughly equal to depreciation and near-neutral working capital — a genuinely asset-light, cash-generative model. The reported FY2/2026 free cash flow of ¥63.7bn overstates the run-rate, inflated by a one-off working-capital reflux, and is not the number to anchor on. The threat to the cash is not operational ; it is the rising debt service on the I&H financing and the choice between M&A and returning capital. The contribution margin of the officine is the one number the consolidated P&L will not show, and it is the number the entire thesis turns on.
This pillar carries the compounder claim. On the one metric that discriminates in this bucket — the spread of return on capital over its cost — Sugi prints 12.0% against ~6%, a +6.0pt spread and first rank alongside Matsukiyo, and it converts that return into the best free cash flow in the sector (ex-growth ¥66.7bn) on an asset-light base (capex 2.3% of sales, working capital near neutral). The gross margin is rising on the officine/OTC mix. The limit is one line down: the EBIT margin has eroded −0.8pt over the decade because SG&A absorbs the gross gain, and organic growth beyond the acquired revenue is low. The compounding is real but capped.
The moat is the second cardinal because it is the reason the stock does not re-rate. It is real but narrow: a pharmaceutical licence that protects the health-aisle margin, a dense network plus the I&H dispensing integration that lifts pharmacist occupancy, and the switching cost of the chronic patient who keeps coming back. What it is not is expansive. Sugi has no pricing power — the retail floor is price-matched, the officine administered — and no monetisable intangible layer: no co-developed private label at a Matsukiyo-style margin, no loyalty-data estate. A moat that defends the existing margin without letting the company extend it earns the middle of the multiple range, not a premium.
Recurring and defensive at the core — the officine at 30.4% of sales, +13.2% same-store, anchored to medical demography, the most captive revenue in the bucket. The drag is the 68% merchandise base, mature at +2.4%, and a consolidated top line whose growth is mostly bought.
Credible on discipline — ROIC held through the deal, the officine pivot well executed — but the allocation record is mixed: chronic under-distribution on a large net-cash balance sheet, I&H debt-financed into a rate normalisation, and a reported profit left to inflate on a non-recurring tax credit before the market was de-risked.
Independent and pure-play, an advantage over the Aeon-controlled Tsuruha, with a dormant balance sheet (~11% of the cap) that TSE pressure could force out. Against it: a thin restitution record — dividend only, ~20% payout, episodic buybacks — that has never earned the re-rating the sector reserves for capital return.
A first-rank compounder held to the middle by its moat and its restitution. The two operating pillars — demand and model — are strong ; the three structural pillars — moat, management, governance — are median. Above a value trap, below a quality compounder such as Food & Life (19–20/25). The grade is consistent with the valuation: no premium on the consolidated line, and once the parts are summed, no discount to claim either. A recognised compounder, correctly priced.
Is the officine accretive or dilutive at the contribution level ?
Is the 2026 fee-schedule revision absorbable, or a margin rupture ?
The market under-weights it. A −2% biennial revision costs 12.6% of gross EBIT on the 30.4% officine share — the most concentrated, most datable regulatory risk in the sector, and the least priced. The net impact is probably smaller than the gross: prescription volume and the dispensing-fee structure partly offset the price cut. But the order of magnitude holds, and the market treats it as diffuse rather than concentrated.
Is a de-rating on the FY2/2027 net-income cliff a buying dislocation ?
The consensus is stuck between “durable rerating” and “accounting false positive,” both reasoning on the net income line. The FY2/2027 cliff — down 27.1% — is purely cosmetic, the reflux of the non-cash tax credit ; the operating line grows +11.2% and Q1 confirms it (+10.9%). The risk, and the opportunity, is that the market prices the headline net income and de-rates a stock whose engine is intact.
At ¥2,968 and ~16.5× normalised forward earnings, the market is pricing a quality compounder executing its plan without a break — return on capital held near 12%, the 2026 fee schedule absorbed, the I&H integration delivered. The +47% rerating over three years already re-rated Sugi from “indebted consolidator” to “quality compounder” ; the recognition has happened. What is not priced is the concentrated fee-schedule downside, the proof that the officine is accretive at contribution, or any acceleration in returning the dormant capital. EV/EBITDA of 7.6× sits exactly on the decade average — not a floor, not a stretch. Valued part by part, the sum falls below the enterprise value the market already assigns.
The 2026 fee schedule comes in worse than −3% and volume does not cover it ; pharmacist wage inflation compounds the squeeze ; the officine turns dilutive at contribution. EBIT compresses ~10% to ~¥46bn and the multiple de-rates with the recovery narrative. The floor holds at ~¥2,320 because net cash, the cash-generative model and the absence of solvency risk underpin it. A timing disappointment, reversible — unless the officine is structurally dilutive, in which case it is permanent.
The plan executes — a −2% fee revision absorbed by demographic volume, the officine modestly accretive, I&H synergies partial, EBITA ~¥51bn. On 17× normalised earnings and ~9.5× EV/EBITA the fair value lands at ~¥2,910, a touch below spot. The consolidated multiple may or may not re-rate ; the fair value does not need it to.
The two un-priced levers fire together. The Yuho proves the officine accretive at contribution, and TSE pressure forces the dormant capital out through a structural buyback — re-rating the multiple to ~20× on a recognised-quality narrative. The path needs both the contribution proof and the allocation decision, and Sugi has answered neither.
| KPI | Latest value | Status | What it tells us |
|---|---|---|---|
| Consolidated EBIT margin | 4.81% FY2/2026 | Cardinal | The contribution tell. Holding above 4.8% as the officine passes 32% of sales confirms positive officine contribution ; erosion below 4.7% confirms the pharmacist is winning and pulls fair value toward the bear. |
| Officine same-store growth | +13.2% Feb 2026 | Holding | The recurring engine, against +2.4% for the drugstore. A fall below +5% at FY2/2027 would break the accretive-migration read even before the fee schedule. |
| Normalised ROIC / spread | 12.0% / +6.0pt | Holding | First rank in the bucket, unaffected by the tax doping (which sits below EBIT). The quality anchor and the reason the bear is a timing disappointment, not a permanent loss. |
| 2026 fee-schedule revision | Pending · Apr 2026 | Trigger | A −2% revision costs 12.6% of gross EBIT. Worse than −3% uncompensated by volume feeds the bear and misses the +11.2% OP guidance ; the most concentrated, least-priced risk in the sector. |
| FY2/2027 OP vs net income | +11.2%e / −27.1%e | Watch | The cosmetic cliff. An OP in line with a de-rating on the headline net income would be a buying dislocation ; the market misreading a non-cash reflux as an operating decline. |
| Capital mobilisation | Dividend only · ~20% payout | Trigger | Dormant capital ~11% of the cap. A structural buyback (>3% of cap/year) or a quantified multi-year return policy is the main un-priced upside and the reason the bull case exists. |
| Officine vs merchandise gross margin | 36.4% / 29.1% | Reference | The +7.2pt mix advantage that compresses to ~+1pt at contribution once the pharmacist is charged. Accretive at the top, thin below. |
| EV/EBITDA (buy-side LTM) | 7.6× | Reference | Exactly the decade average (7.7×). Not a floor, not a stretch ; compression below ~6× on intact fundamentals would open a LONG window. |
The case turns positive on either of two proofs. The Yuho segmental note showing the officine clearly accretive at contribution once the pharmacist is charged, or a quantified multi-year policy that puts the dormant balance sheet to work, would move the dossier from watchlist to long. A third, faster path is a de-rating of more than 15% on the FY2/2027 headline net-income cliff with the operating line intact — a dislocation created by the market misreading a non-cash reflux as an operating decline. Each is observable ; none is signalled today.
The case turns negative if the scissor closes the wrong way. A 2026 fee revision worse than −3%, uncompensated by volume, would miss the operating guidance and de-rate the stock toward ~¥2,320. Worse would be the officine turning structurally dilutive at contribution — the pharmacist durably eating more than the gross-margin edge — because that is the one path from a timing disappointment to a permanent impairment.
The allocation risk is the one to watch most carefully, because the company has the balance sheet and the appetite for it. A further debt-financed acquisition at an incremental return below the cost of capital, made as interest cover tightens and BoJ rates rise, would immobilise capital in pure loss and degrade an already-stretched balance sheet — a more tangible route to irreversible destruction than the fee schedule. Currently not signalled.
The information provided on this website is for informational and educational purposes only and should not be construed as financial, investment, legal, or tax advice. All content reflects the personal opinions, interpretations, and analyses of the author at the time of writing and is subject to change without notice. Nothing contained herein constitutes, or should be interpreted as, a recommendation, solicitation, or offer to buy or sell any securities, financial instruments, or other investment products. The author is not a licensed financial advisor, broker, or investment professional. Any references to specific assets, markets, or strategies are illustrative in nature and do not constitute personalized investment advice. Investing in financial markets involves risk, including the potential loss of capital. Past performance is not indicative of future results. Readers are solely responsible for their own investment decisions and should conduct their own independent research and due diligence before making any financial commitments. You are strongly encouraged to consult with a qualified financial advisor, legal professional, or other relevant specialist before making any investment or financial decisions. By accessing and using this blog, you agree that the author shall not be held liable for any direct or indirect losses, damages, or consequences arising from the use of, or reliance on, the information presented herein. All content is provided "as is" without any warranties of completeness, accuracy, or reliability.